CCDC69 and urinary bladder cancer: In the ICI-treated patient cohort of Camoip database, we found that higher expression level of CCDC69 could predict better immunotherapy benefits in bladder cancer, as shown by OS (HR = 0.76, 95%CI (0.58–0.98), p = 0.034) (Fig. 12A).